New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
05:25 EDTCTICCell Therapeutics opens enrollment for PERSIST-2 Phase 3 trial of pacritinib
Cell Therapeutics announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter. The trial is expected to enroll up to 300 patients in North America, Europe, Australia and New Zealand within 12 to 14 months. In October 2013, CTI reached agreement with the FDA on a Special Protocol Assessment for the PERSIST-2 trial, which is a written agreement between CTI and the FDA regarding the planned design, endpoints and statistical analysis approach of the trial to be used in support of a potential New Drug Application, or NDA, submission. PERSIST-2 is the second of two planned Phase 3 trials in the pacritinib development program for myelofibrosis.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
16:54 EDTCTICCTI BioPharma files to sell 9M shares of common stock for holders
16:40 EDTCTICCTI BioPharma files $200M mixed securities shelf
Subscribe for More Information
November 19, 2014
07:09 EDTCTICJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 17, 2014
11:06 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
November 13, 2014
13:32 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
November 11, 2014
16:14 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use